{"filing":{"accession_number":"0001104659-26-087269","cik":"0001374339","ticker":"PMN","company_name":"ProMIS Neurosciences Inc.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"pmn-20260728x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm"},"events":[{"id":20842,"run_id":18763,"accession_number":"0001104659-26-087269","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"ProMIS disclosed positive blinded six-month interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease patients, showing favorable safety findings (no ARIA-E observed, 4.4% total ARIA), early biomarker movement consistent with target engagement (68.5% decline in pTau217, 62.5% decline in MTBR-tau243), and a clear path to 12-month topline results expected in Q1 2027. This material clinical development milestone de-risks the lead program and affects investor assessment of the company's pipeline progress.","company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20331,"accession_number":"0001104659-26-087269","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ProMIS disclosed positive blinded six-month interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease patients. The disclosure highlights favorable safety findings (no ARIA-E observed, 4.4% total ARIA), early biomarker movement consistent with target engagement, and a clear path to 12-month topline results in Q1 2027. This is a material clinical trial milestone for a clinical-stage biopharmaceutical company with peak sales potential exceeding $10B, affecting investor assessment of the lead program's viability and de-risking the development pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:10:28.352520+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20332,"accession_number":"0001104659-26-087269","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ProMIS disclosed positive blinded interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease patients. The disclosure highlights favorable safety findings (no ARIA-E observed, 4.4% total ARIA), early biomarker movement consistent with target engagement (68.5% decline in pTau217, 62.5% decline in MTBR-tau243), and a clear path to unblinded 12-month topline results expected Q1 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company's lead product candidate, but it is not a financial result, M\u0026A activity, executive change, or other specifically-named event type. It represents a significant operational/clinical milestone that would affect investor assessment of the company's pipeline progress and probability of success.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:10:28.352520+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20331,"accession_number":"0001104659-26-087269","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ProMIS disclosed positive blinded six-month interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease patients. The disclosure highlights favorable safety findings (no ARIA-E observed, 4.4% total ARIA), early biomarker movement consistent with target engagement, and a clear path to 12-month topline results in Q1 2027. This is a material clinical trial milestone for a clinical-stage biopharmaceutical company with peak sales potential exceeding $10B, affecting investor assessment of the lead program's viability and de-risking the development pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:10:28.352520+00:00","company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","filing_date":"2026-07-28"},{"id":20332,"accession_number":"0001104659-26-087269","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ProMIS disclosed positive blinded interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease patients. The disclosure highlights favorable safety findings (no ARIA-E observed, 4.4% total ARIA), early biomarker movement consistent with target engagement (68.5% decline in pTau217, 62.5% decline in MTBR-tau243), and a clear path to unblinded 12-month topline results expected Q1 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company's lead product candidate, but it is not a financial result, M\u0026A activity, executive change, or other specifically-named event type. It represents a significant operational/clinical milestone that would affect investor assessment of the company's pipeline progress and probability of success.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:10:28.352520+00:00","company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","filing_date":"2026-07-28"}]}